Jump to Main Content
- Smider, Vaughn V., et al. Show all 21 Authors
- Proceedings of the National Academy of Sciences of the United States of America 2012 v.109 no.40 pp. 16101-16106
- Escherichia coli; antibodies; cysteine; cytotoxicity; drugs; immunoglobulin G; lysine; medicinal properties; models; mutants; neoplasm cells; neoplasms; pharmacokinetics; remission; rodents; stoichiometry
- ... Antibody-drug conjugates (ADCs) allow selective targeting of cytotoxic drugs to cancer cells presenting tumor-associated surface markers, thereby minimizing systemic toxicity. Traditionally, the drug is conjugated nonselectively to cysteine or lysine residues in the antibody. However, these strategies often lead to heterogeneous products, which make optimization of the biological, physical, and ph ...
- PubMed Central: